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Introduction: Despite the strong evidence of the clinical utility of QTc prolongation as a
surrogate marker of cardiac risk, QTc measurement is not part of clinical routine either in hospital
or in physician ofﬁces. We evaluated a novel device (“the QT scale”) to measure heart rate (HR)
and QTc interval.
Method: The QT scale is a weight scale embedding an ECG acquisition system with four limb
sensors (feet and hands: lead I, II, and III). We evaluated the reliability of QT scale in healthy
subjects (cohort 1) and cardiac patients (cohorts 2 and 3) considering a learning (cohort 2) and
two validation cohorts. The QT scale and the standard 12-lead recorder were compared using
intraclass correlation coefﬁcient (ICC) in cohorts 2 and 3. Absolute value of heart rate and QTc
intervals between manual and automatic measurements using ECGs from the QT scale and a
clinical device were compared in cohort 1.
Results: We enrolled 16 subjects in cohort 1 (8 w, 8 m; 32  8 vs 34  10 years, P = 0.7),
51 patients in cohort 2 (13 w, 38 m; 61  16 vs 58  18 years, P = 0.6), and 13 AF patients in
cohort 3 (4 w, 9 m; 63  10 vs 64  10 years, P = 0.9). Similar automatic heart rate and QTc
were delivered by the scale and the clinical device in cohort 1: paired difference in RR and QTc
were 7  34 milliseconds (P = 0.37) and 3.4  28.6 milliseconds (P = 0.64), respectively. The
measurement of stability was slightly lower in ECG from the QT scale than from the clinical
device (ICC: 91% vs 80%) in cohort 3.
Conclusion: The “QT scale device” delivers valid heart rate and QTc interval measurements.
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A prolonged QTc has been recognized as a nonin-
vasive risk marker for cardiovascular diseases,
sudden death, stroke, and all-cause cardiovascular
mortality.1 With the aging population worldwide,
the number of patients exposed to drug therapies
with potential QT prolongation effect will
increase. However, despite the strong evidence of
the clinical utility of QT/QTc prolongation as a
surrogate marker of cardiac risk, QT/QTc interval
measurement is not part of general clinical
routine either inside the hospital or in regular
physician offices. Recently, this lack of awareness
about a patient susceptibility to develop QT-
related arrhythmias has been highlighted in a
statement of the American Heart Association,2
emphasizing the need to integrate QT monitoring
in hospital to reduce the number of torsades de
pointes (a life-threatening cardiac arrhythmia).
In this project, we describe a proof-of-concept
study evaluating the ability of a new type of
device designed to quickly perform a QT/QTc
interval measurement at the time of a medical
visit. The so-called QT scale is a technical solution
to enable healthcare providers to get a patients
heart rate and QTc intervals without using a stan-
dard ECG recorder and without significantly
changing their medical routines. We present a pre-
liminary evaluation of this device to deliver QT/
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QTc interval measurements in three cohorts of
patients: general subjects (cohort 1), cardiac
patients going through the inpatient clinic (Clinical
Cardiology Division at the University of Rochester
Medical Center, Rochester, NY, USA) (cohort 2),
and patients with atrial fibrillation (AF) hospital-
ized for dofetilide treatment (cohort 3). We opted to
use the ECG from the second cohort as a learning
set in order to develop a reliable fully automatic QT
measurement algorithm for ECG signals recorded
with the QT scale. Thereafter, we evaluated the
measurement technique in the remaining cohorts
(1 and 3). We assessed the ability of the device to
measure the QT interval in healthy subjects and
more challenging set of ECGs with nonsinus
rhythm and drug-induced changes in QT intervals.
METHODS
Study Populations and Protocol
We enrolled two cohorts of cardiac patients and
one cohort of healthy individuals.
Cohort 1
This first cohort includes healthy individuals
(noncardiac patients) enrolled inside a single pri-
vate organization (iCardiac Technologies Inc.,
Rochester, NY, USA). A single ECG signal was
recorded in each individual using a clinical 12-
lead ECG system and the QT scale device to test
the ability of the QT scale to records the ECG sig-
nal. These ECGs were recorded simultaneously
while the subjects were comfortably sitting in a
chair. The subject kept their socks on during the
recording. The data from this first cohort was
used to first evaluate the hardware of the QT
scale and second assess its ability to deliver accu-
rate heart rate and QTc interval measurements.
Cohort 2
The cohort 2 included cardiac patients from the
Inpatient Clinic at the University of Rochester
Medical Center (Rochester, NY, USA). Purposely,
any cardiac patients with very diverse type of car-
diac diseases were enrolled (inpatients). In this
cohort, two clinical ECGs were acquired 1 minute
apart, and then the subject was asked to stand for
a couple of minutes and step on the weight scale to
acquire two scale ECGs 1 minute apart.
Cohort 3
The third cohort (cohort 3) included patients
going through a dofetilide protocol for drug-
induced cardioversion of atrial fibrillation. We
selected this cohort for two reasons: (i) this drug
induces dramatic effect on the T wave morphol-
ogy (Ikr blocker) by flattening its amplitude and
therefore will challenge the automatic QT inter-
val measurements, and (ii) these patients will be
in AF during their first ECG. Three recording ses-
sions per subject were implemented in this
cohort: session 1, baseline recording prior to first
dose of dofetilide; session 2, prior to second dose
of dofetilide; and session 3, prior to hospital
release and just after last dose administration.
During each session, we acquired two ECGs
(replicate ECGs) in standing position on the scale
(SCALE) and two ECGs using a clinical 12-lead
ECG in supine position. The subjects in cohort 3
were in AF rhythm during their baseline record-
ings and possibly in the subsequent ones.
The enrollment criteria were similar for the
two cohorts of cardiac patients (cohorts 2 and 3),
i.e., adult cardiac patients (age ≥ 18 years). We
excluded patients who could not comply with the
use of the weight scale and patients with muscu-
lar tremors and/or Parkinson disease. The proto-
col was approved by the University of Rochester
(Rochester, NY, USA) Research Review Board.
The Clinical ECGs
From the clinical 12-lead ECG devices (clinical
ECG), the QT and RR measurements were
extracted from commercial systems: the M12A
(Global Instrumentation, Syracuse, NY, USA) for
cohort 1 and the RR intervals were measured by
Hscribe (Mortara Instruments, Milwaukee, WI,
USA) for cohorts 2 and 3. The manual measure-
ments of the QT intervals were extracted from
lead II by ECG experts (Manual) using paper trac-
ings printed from the clinical device and mea-
sured on computer screen for the scale ECGs.
The QT Scale
The QT scale prototype is a simple electronic
weight scale (commercially available) to which a
set of four sensors have been integrated to mea-
sure the body surface ECG from the subjects
limbs. These sensors are designed to be in contact
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with the feet of the patient when he/she steps on
the scale, and the two remaining sensors are
hand sensors with the shape of a chicken egg
(Fig. 1). The four-hand and feet electrodes are
connected to a box that contains the electronic
components for the recording and the processing
of the signal acquired from the subjects limbs.
System bandwidth is 0.05–100 Hz, resolution 16
bit, and sampling rate 1 kHz. The QT scale is con-
nected to a laptop (running on its battery)
through USB 3.0 port, which delivers 5.00 V
power source. The hand and feet electrodes were
disinfected using alcohol-based sanitizer. This
device complies with the FDA 809.10(c), and it
does not require an invasive sampling procedure
that presents significant procedure energy into a
subject, and it is not designed to introduce energy
into the subject. The prototype used in this study
will be ultimately designed to embed all pieces
described in Figure 1B in one single device unit
(the scale).
QT and RR Measurements from the Scale
ECG Device
From the QT scale device (Scale ECG), we mea-
sured heart rate automatically (Scale ECG RR),
while QTc interval were measured both manually
(Scale ECG Manual QTc) and automatically (Scale
ECG Automatic QTc) from all limb leads recorded
by the scale device (using a representative beat
approach). The algorithm for QRS onset and
T wave end detection was designed based on
manual annotation from data of the cohort 2. We
Figure 1. The “QT scale” is a device integrating both a weight scale and an ECG recorder. It records the ECG signals
from the limb leads (Einthoven triangle, i.e., leads I, II, and III). The device includes both feet and hand sensors to
record a three-lead electrocardiogram and to deliver the measurements of heart rate and heart rate–corrected QT
measurements. (A) the prototype in use; (B) the device schematic presentation; (C) the user interface of the system for
gender selection; (D) the screen display during recording, and (E) the user interface reporting the measurements. The
system requires the subject to be standing for 60 seconds.
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expected lower quality of the ECG signals
recorded with the QT scale device (Scale ECG)
than with the clinical ECG devices3 because of
the higher impedance of skin–electrode interface
for dry electrodes and electromyogram noise
when the subject is standing.
We developed a set of digital processing proce-
dures to strongly reduce the noise of the ECG sig-
nal and enhance the QRS and repolarization
signal (ST-T segment). These procedures include
multiple components: signal noise estimation,
lead consistency check, and combination of lead
signals (root mean square signals). The QRS
detection algorithm is a unique fully automatic
method based on (i) an adaptive threshold detec-
tion of cardiac beats, (ii) computation of a beat
template, and (iii) a cross-correlation technique
using the beat template to eliminate the beats
with inconsistent morphology. Subsequently, a
template-based signal-averaging technique is
recomputed and used to generate a final repre-
sentative beat from which QTc intervals are mea-
sured. The system includes two different
algorithms for the identification of the end of the
T wave. The average results from the two meth-
ods are reported (differential threshold and slope
intercept methods).4 The Bazetts formula was
used to correct QT interval from heart rate
because it is the most clinically used method;
however, we also report the QTc interval based
on Fridericias correction for the cohort 3 in
which the drug is associated with significant
changes in heart rate.
Statistics
In cohort 1, we have recorded the standard ECGs
and scale ECG in the same condition (sitting posi-
tion) enabling a direct comparison of the interval
measurements between devices (RR and QTc
intervals). We used the Bland–Altman method5 to
assess the level of agreement between QTc interval
measurements between the two recording tech-
nologies. In cohorts 2 and 3, ECGs were recorded
using different body position leading to different
QTc interval measurements because of the differ-
ence in autonomic state (and heart rate). There-
fore, we will not compare QTc values in supine
and standing recordings between measurements
methods, but we will compare the level of variabil-
ity of these measurements in these different pos-
tures (across patients and between replicate
ECGs). The assessment of the QT scale reliability
will rely on the intraclass correlation (ICC) com-
puted on the replicated ECGs across the whole
recordings of the second cohort consisting of AF
patients.6 Reliability (ICC) is reported as a number
between 0 and 100 (in percent), and high reliability
(ICC = 100%) means that the difference between
the successive measurements are true and do not
include measurement errors. The ICC values for
standard and scale ECG devices will be compared.
These measures of reliability and stability were
compared between recording devices and between
measurement techniques.
When comparing simultaneous measurement
of RR and QT in the healthy cohort, we tested
whether the difference between the compared
approaches was not statistically different from
zero using paired and nonpaired t-test or non-
parametric Wilcoxon test when appropriate.
RESULTS
The enrollment period of the study lasted for
5 months spanning between February and June
2015. We enrolled 16 subjects in cohort 1, 54
patients in cohort 2, and 13 patients in cohort 3.
Three subjects were withdrawn from the study in
cohort 2 for reasons independent from the study.
Learning Set: Cohort 2
Cohort 2 included 38 males and 13 females
(58  18 vs 61  16 years, P = 0.6), 2 of the male
subjects were African American while the rest of
the cohort were Caucasians.
For the clinical ECGs, the manual QTc mea-
surements could not be done in 3 ECGs of 102
paper tracings (2.9%). Two ECGs (replicate) from
the same individual had poor quality signals
because these ECG tracings had low-amplitude
T wave and QT interval could not be extracted.
In the third recording, RR could not be mea-
sured. As a note, the commercial machine did not
deliver automatic QTc interval measurements in
these three ECGs.
Initially, among the 51 subjects and 102 scale
ECG recordings recorded in this cohort, 16
recordings (31.3%) did not have either the RR or/
and the QT interval available. By tuning in the
detection algorithm, we reduced the number of
ECGs in which the measurements could not be
done to 5 (4.9%). One subject did not have any
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ECG with quality high enough to extract the
ECG intervals, and three subjects had only one of
the two ECGs in which QT and RR could be mea-
sured. Therefore, 98% of subjects had at least
one successful recording on which the QT and
RR could be measured.
Ultimately, the average and standard deviation
of heart rate values were 69  14 versus
78  17 bpm (P < 0.001) between the clinical
ECGs and the scale ECGs, reflecting the changes
in body position, that is, supine versus standing.
The QTc intervals durations were equal to
470  72 versus 465  60 milliseconds (P = 0.74)
for the clinical versus scale ECGs, respectively.
These results were based on average values from
replicated ECGs. The intravariability, intervari-
ability, and the ICC for QTc intervals and heart
rate measurements in this learning set were as
follows: the most stable results for QTc were
obtained for the manual method (95%) while the
automatic from the QT scale was equal to 81%.
The ICC measures of RR interval were the high-
est for the QT scale (99%) and slightly lower in
standard ECG (97%).
Validation Set: Cohort 1 and Cohort 3
In cohort 1, we enrolled 16 subjects including
eight women and eight men (32  8 vs
34  10 years, P = 0.7). All subjects were Cau-
casian except for one individual: African-Ameri-
can woman. Similar heart rate and QTc were
delivered by the scale and the clinical device:
paired difference in RR and QTc were
7  34 milliseconds (P = 0.37) and
3.4  28.6 milliseconds (P = 0.64), respectively.
In Figure 2, we report the Bland–Altman (BA)
plots to evaluate the level of agreement between
measurement methods and recording devices.
Specifically in this figure, the panel A displays the
paired comparison between RR interval measure-
ments (fully automatic measurements and mean
from all replicates) between the clinical and the
scale devices; in panel B, the BA plot shows the
differences between automatic QTc measure-
ments from the clinical and scale devices; in
panel C, the manual QTc measurements from
clinical and scale devices, and finally in Panel D,
the manual versus automatic QTc interval from
ECGs recorded using the scale device. The only
statistically significant difference was found
between manual QTc measurements from the
clinical and scale device. When investigating
paired differences of QTc interval for manual
QTc measured from the signal acquired by the
clinical and the scale device, we found that QTc
from clinical device was 30  28 milliseconds
(P = 0.007) longer than from the scale ECG.
Importantly, none of the Bland–Altman plot
shows any trend toward a biased agreement
between methods.
In cohort 3, we enrolled 13 cardiac patients
suffering from atrial fibrillation (AF), nine men
and four women (64  10 vs 63  11 years,
P = 0.93), all Caucasian. One of the subjects was
withdrawn after refusing to participate post
enrollment. Among the 12 remaining subjects,
eight subjects had three recordings sessions (two
standard ECGs and two QT scale measurements).
One patient had withdrawn after the first record-
ing session. One subject was discharged before
the last dose of dofetilide, and therefore, only the
two first sessions were recorded. One of the sub-
jects had only one recording session because of a
failure of the QT scale hardware, which led to
stopping the recording protocol. The technical
problem was troubleshooted and an internal fuse
failure was fixed. Three recordings from the clini-
cal ECG system did not work properly, and the
quality of the recordings was so poor that the
interpretation, the QT, and the RR intervals were
either unavailable or out of normal range (these
were manually checked).
We report in Table 1 the heart rate (HR) mea-
surements from the validation set for the base-
line, after the first dose, and after the last dose of
dofetilide between the clinical ECG and
scale ECGs. There was no statistical difference
between the values despite a slightly higher HR
reported during the scale measurements that
were expected for different body position
(82  20 vs 74  19 bpm, P = 0.13, when merg-
ing all periods). The metrics of stability of RR
measurements (ICC, intrareplicates, and intersub-
jects) are reported in Table 2. The average ICC
across the three recordings periods (baseline,
after the first dose, and after the last dose) for
HR is 97% for both the QT scale and the clinical
device (clinical ECG).
Table 1A reports the heart rate measurements.
The QTc values for automatic and manual read-
ing from the scale ECGs were 471  58 versus
489  50 milliseconds (P = 0.23), respectively,
across all periods. The average and standard
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deviation of QTc values per periods are reported
in Table 1B. Dofetilide lowered heart rate and
increased QTc interval durations. After the first
dose of dofetilide, the QTc increased when using
the Fridericias correction: +23 and +12 millisec-
onds for the manual and automatic method,
respectively; while QTc intervals is not strongly
affected by the drug when using the Bazetts for-
mula (+8 and 2 milliseconds).
In Table 2, we report the ICC (reliability) for
HR and QTc. For the clinical ECG machine, the
ICC for the QTc is 91% for the manual methods,
while for the scale ECG, the ICC are 60% and
80% for the manual and automatic methods,
respectively. The values of ICC are summarized
in Figure 3 for RR and QTc measurement across
measurement methods.
The clinical impact of the higher variability of
short-term QTc measurement in the clinical
realm is not expected to be significant in the
general population. However, in patients with
prolonged QTc, an increased variability may lead
to increase the number of false results or low
sensitivity and specificity. To illustrate this limi-
tation, we computed the percentage of replicated
ECGs showing inconsistent results when using
specific limits for QTc values to detect the pres-
ence of an abnormal QTc interval duration, such
as QTc > 500 milliseconds. We varied this
threshold from 450 to 550 milliseconds and com-
puted the percentage of session during which
replicated ECGs are inconsistent. We report this
percentage from the learning set of data in
Figure 4.
Figure 2. Bland–Altman plots describing the level of agreement for the RR and QTc interval measurements across
measurement methods and recordings devices. Bland–Altman plots for: (A) the automatic RR intervals between clinical
and scale devices; (B) the automatic QTc between clinical and scale devices; (C) the manual QTc between the clinical
and scale devices; and (D) the manual and automatic QTc from the scale device.
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As expected, the intrareplicate variability is
lower than the intersubject one for all methods.
Specifically, the manual QTc measurement from
the scale had the worse stability (low reliability)
in the set of ECGs recorded after the last dose.
These were explained by abnormal T wave mor-
phology (very flat amplitude) across replicate
ECGs. In Figure 5, we report examples of three
ECG tracings from cohorts 2 and 3 with good-
quality measurements and one tracing with high
variability from the scale. In such cases, the algo-
rithm behaves very consistently but manual mea-
surements are very variable. In Table 3, we
report the HR and QTc values per replicate
ECGs; there were no statistical differences
between first (M1) and second (M2) recording.
DISCUSSION
In this work, we propose to integrate an ECG
recorder into a weight scale and to test its ability
to deliver reliable QTc interval measurements to
reduce the constraints described above. We
implemented an investigational study in which
the QT scale, a weight scale embedding a 3-lead
ECG recorder, was used in cardiac patients to
Table 1. Heart Rate and QTc Measurements in the Cohort 3 (mean  SD)
A
HR (bpm)
Clinical ECG Scale ECG
Baseline 84  21 94  22
After ﬁrst dose 67  12 78  17
After last dose 62  10 71  13
B (Scale ECG)
QTc (milliseconds) (Bazett) QTc (milliseconds) (Fridericia)
Manual Automatic Manual Automatic
Baseline 487  58 481  63 453  42 447  44
After ﬁrst dose 495  53 479  62 476  51 459  50
After last dose 485  41 452  50 473  39 440  42
None of the comparison between values of heart rate from the clinical and the scale average was statistically signiﬁcant. None of
the comparison between manual and automatic average values was statistically signiﬁcant.
Table 2. Intraclass Coefﬁcients and Intravariability/
Intervariability of QTc Interval and Heart Rate in the
Validation Cohort (Cohort 3)
ICC (n)
HR QTc
Device
ECG
Scale
ECG
Scale
ECG
Manual
Scale
ECG
Automatic
Baseline 99 (12) 96 (11) 56 (11) 80 (11)
After ﬁrst
dose
95 (10) 99 (9) 75 (9) 82 (9)
After last
dose
96 (8) 96 (9) 48 (9) 77 (9)
ICC is expressed in percent, and the number between paren-
thesis indicates the number of subjects in each group of mea-
surements.
Figure 3. Intraclass coefﬁcient (ICC) of the QTc and RR
interval measurements computed for the three sets of
data from cohort 3, i.e., at baseline after the ﬁrst dose
of dofetilide, and after the last dose of dofetilide. ICCs
for the automatic heart rate measurements from a clini-
cal device and from the scale ECGs are on the right
side, and the manual and automatic QTc intervals from
the ECG recorded with the scale device are reported on
the left side.
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measure heart rate and QT intervals. The scale
device was built by a group from Technical
University of Catalonia (Barcelona, Spain) (ESF,
OC, RPA) by simplifying a previous design,7
while the University of Rochester (JPC, XN)
designed and integrated a software interface
delivering the measurements of the RR and QT
intervals from the ECG signal acquired with the
scale. The QT measurement methods were opti-
mized using visual adjudication of the end of the
T wave with a set of recordings acquired in car-
diac patients. Then, we evaluated in an indepen-
dent set of ECGs recorded in cardiac patients
with AF exposed to QT-prolonging drug (dofeti-
lide) and in a set of presumed healthy subjects.
The QT scale devices generated slightly lower sta-
bility than standard 12-lead ECGs (ICC: 91% vs
80%) for QTc interval measurements and equiva-
lent stability for heart rate measurements.
The QTc prolongation on the surface electrocar-
diogram is an independent risk factor for sudden
cardiac death in the general population,8,9 in
infants during the first week of life (sudden infant
death syndrome),10 and it is a significant indepen-
dent marker of risk for cardiac events in the
acquired11 and inherited12 forms of the long QT
syndrome (LQTS). In critical care units, the QTc
monitoring is recommended to identify these
patients with risk of torsades de pointes.13,14 In
the general population, the prevalence of the con-
genital LQTS is estimated to 1 in 2000–2500 live
birth,15 while the prevalence of drug-induced
QTc prolongation is expected to be much larger
because of the large families of drugs associated
with risk of QTc prolongation which include
antiarrhythmics, antihistamines, antimicrobials,
antidepressants, and neuroleptics, among others.
Regulatory bodies have regulated the access to
the market of QT-prolonging drugs,16 but many
drugs are still prescribed by health professional
that bear the risk for adverse events linked to
QTc prolongation such as torsades de pointes
either by themselves and/or by interaction with
other drugs, and/or by patients intrinsic suscepti-
bility (genetic variants). The pool of patients
exposed to these potential QT-prolonging drugs is
Figure 4. The three curves present the percentage of inconsistent ﬁndings when the QTc interval is used to identify
the presence of abnormal QTc using a threshold varying from 450 to 500 milliseconds. Hundred percent means that
none of the replicate ECGs are consistently showing values below the selected threshold, while 0% means that all
replicate ECGs are consistently showing values below the selected threshold. The darker curve presents the perfor-
mance of a manual reader using standard 12-lead ECG tracing, while the dotted gray curve the performance by the
same reader using the electrocardiogram from the QT scale. Finally, the continuous gray curve is the performance of
the automatic measurement from the QT scale ECG signals.
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large, but the number of patients developing
harmful QTc interval prolongation is expected to
be low. This explains partially why the ECG
screening for QTc prolongation is not routinely
implemented in the general population but also
in more specific groups of subjects such as
infants despite the fact that cost-effectiveness of
screening was studied and reported to be accept-
able.10
One of the major costs associated with QT
screening resides in the time and resources
needed to obtain a QT/QTc interval measure-
ment. These resources are multiple: access to a
specific and dedicated device (ECG recorder), a
Figure 5. The ECG tracings from the QT scale: in cohort 2 (top and bottom left) for good-quality signals where man-
ual and automatic QTc measurements are close, and before and after dofetilide in cohort 3 (top and bottom right,
respectively) for the same subject. In this latter example, the drug has been associated with strong changes in T wave
morphology and especially lowering of the T wave amplitude where the identiﬁcation of the end of the T wave
becomes challenging.
Table 3. Heart Rate and QTc Measurements (Mean  SD) per Replicate ECGs
Cohort 3 (Validation)
HR (bpm) QTc (milliseconds)
Clinical ECG Scale ECG
Scale ECG
Automatic Automatic Manual Automatic
M1 74  18 (29) 81  20 (28) 478  55 (27) 461  64 (28)
M2 73  19 (30) 83  21 (29) 497  56 (30) 483  65 (29)
P-value* 0.94 0.69 0.21 0.19
*Test if the averaged delta values are signiﬁcantly different from 0 between replicate ECGs. The numbers between parenthesis
report the number of ECGs used to compute the statistics.
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competent and trained ECG operator, the time
for patients skin preparation and electrode place-
ment, and time for recording and conducting
interpretation. Therefore, the integration cost of
QTc screening into any health care framework is
expected to be significant.
The major challenge in using the scale ECG
was to ensure a good quality of the ECG signal.
In the learning cohort, two subjects had ECG sig-
nals of very low quality in which neither the QΤ
interval nor the heart rate could be measured.
This lack of signal quality was explained by inap-
propriate contact between the device sensors and
the limbs of the patients, specifically the feet.
The next version of the device will be revised to
integrate sensors that have larger contact surface.
Furthermore, the patient may have difficulty to
stand still on the scale specifically those patients
who are obese. Movement during the recording
generated substantial noise that influenced the
stability of the recordings (this was not quantified
but observed during the recording periods).
To conclude, we believe the proposed concept
is interesting because it would enable an easy
integration of QTc measurement to any clinical,
physical health, or even home routines. This con-
cept benefits from three major characteristics: (i)
it could deliver QTc measurement without con-
sidering a dedicated equipment, (ii) it is easily
integrated by being combined with standard
health routine (i.e., weight measurements), and
(iii) it does not require ECG-trained individual to
record the surface ECG and measure the QT/QTc
interval.
LIMITATIONS
We believe that the differences in QTc measure-
ments between the two recordings systems would
be driven by differences in body position (seating,
standing, and supine) and number of leads avail-
able (limb leads vs standard 12-lead system).
Therefore, the assessment of the QT scale value
was based on the ICC values providing insights
into QTc measurement stability and repeatability
in cohort 3. In cohort 1, standard ECG and QT
scale ECGs were recorded simultaneously
enabling a direct comparison of heart rate and
QTc values.
One would note that the lower stability for the
period on drug may be due to the lower heart
rate. Since the scale algorithm depends on a sig-
nal-averaging technique from 1-minute recording
period, in patients with lower heart rate, the sig-
nal contains a lower number of beats and there-
fore lower signal-to-noise values. This limitation
may be avoided in the future by recordings for a
specific number of beats.
Finally, the device deserves to be tested thor-
oughly in patients with definitive drug-induced
long QT syndrome, specifically in these patients
treated with QT-prolonging drugs with reverse
use dependency effect.17 We propose to acquire
ECG in standing position; therefore, the QTc pro-
longing effect may be masked due to the
increased heart rate associated with a standing
position. More investigation is needed to eluci-
date the effect of body position.
CONCLUSIONS
We investigated the use of a weight scale for inte-
grating QT intervals in clinical routine without
involving standard 12-lead ECG and therefore
minimizing the time and cost of getting a valu-
able electrocardiographic measurement. The
device shows reliable and stable assessment of
heart rate and QTc intervals. The design of the
device is to be improved and evaluated in a larger
cohort of patients.
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